Article Text

Multilink Stent Promotes Less Platelet and Leukocyte Adhesion Than a Traditional Stainless Steel Stent
  1. Giovanni Amoroso,
  2. Ad J. van Boven,
  3. Corine Volkers,
  4. Harry J.G.M. Crijns,
  5. Wim van Oeveren
  1. From the Department of Cardiology (G.A., A.J.B., H.J.C.), University of Groningen, Groningen, the Netherlands
  2. Trial Coordination Centre (C.V.), Thoraxcentre, University of Groningen, Groningen, the Netherlands
  3. Department of Biochemical Engineering (W.O.), University of Groningen, Groningen, the Netherlands.
  1. Address correspondence to: Giovanni Amoroso, MD, Department of Cardiology, Thoraxcentre, University Hospital of Groningen, Hanzeplein 1, PO Box 30 001, 9700 RB Groningen, the Netherlands. E-mail g.amoroso{at}

An In Vitro Experimental Study


Background Platelet and leukocyte deposition onto metallic struts can be a crucial factor in the outcome of a coronary stenting procedure. By means of an in vitro, closed-loop circulation model, we aimed to assess blood-stent interaction patterns for a new stainless steel stent (MultiLink, Guidant Nederland BV, Nieuwegein, the Netherlands).

Methods The effect of MultiLink (n=20) on blood cells and blood activation was studied by biochemical assays. Platelet and leukocyte adhesion to MultiLink were studied by immunofluorocytometric assays (anti-GpIIIa [CD 61] and anti-CD11b labeled antibodies, respectively), and by scanning electron microscopy. MultiLink was compared with empty circuits (n=20) and to the Palmaz Schatz stent (n=20). Experiments were performed both in the presence and in the absence of an antiplatelet agent (15 μg/mL of indomethacin).

Results No significant effect on blood cells and blood activation was demonstrated for MultiLink. Antiplatelet treatment significantly reduced platelet adhesion to MultiLink (from 3.78±1.28 to 2.23±0.57x106 count per second [cps]/stent) but not to the Palmaz Schatz stent (from 4.11±0.31 to 5.02±1.29x106 cps/stent)(P=0.011). Leukocyte adhesion to MultiLink was significantly less than adhesion to the Palmaz Schatz stent (7.95±1.59 vs. 9.16±1.36x106 cps/stent, respectively; P=0.016), regardless of the presence of antiplatelet treatment.

Conclusions When compared with a traditional stainless steel stent, MultiLink seems to have features of improved hemocompatibility, and single antiplatelet treatment is proposed as the treatment of choice to prevent platelet deposition.

Key words
  • stents
  • leukocytes
  • platelets
  • adhesion
  • antiaggregant
  • hemocompatibility

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.